Defactinib
- Generic Name
- Defactinib
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21F3N8O3S
- CAS Number
- 1073154-85-4
- Unique Ingredient Identifier
- 53O87HA2QU
- Background
Defactinib has been investigated for the treatment of Malignant Pleural Mesothelioma.
5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours
- Conditions
- Glioblastoma Multiforme (GBM)Glioblastoma Multiform (Grade IV Astrocytoma)Diffuse Hemispheric Glioma, H3 G34-MutantMalignant Primary Gliomas
- Interventions
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Institute of Cancer Research, United Kingdom
- Target Recruit Count
- 182
- Registration Number
- NCT06630260
- Locations
- π¬π§
Cambridge University Hospitals, Cambridge, United Kingdom
π¬π§The Royal Marsden Hospital - Drug Development Unit, Sutton, United Kingdom
π¬π§The Royal Marsden Hospital - Neuro-Oncology Unit, Sutton, United Kingdom
Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer
- Conditions
- Advanced Lung AdenocarcinomaRefractory Lung AdenocarcinomaStage III Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Positron Emission Tomography
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Emory University
- Target Recruit Count
- 50
- Registration Number
- NCT06495125
- Locations
- πΊπΈ
Emory University Hospital Midtown, Atlanta, Georgia, United States
πΊπΈEmory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
πΊπΈEmory Saint Joseph's Hospital, Atlanta, Georgia, United States
Avutometinib and Defactinib in Diffuse Gastric Cancer
- Conditions
- Gastric CancerStomach Cancer
- Interventions
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Ryan H. Moy, MD, PhD
- Target Recruit Count
- 27
- Registration Number
- NCT06487221
- Locations
- πΊπΈ
Columbia University Irving Medical Center, New York, New York, United States
A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer
- Conditions
- Low-Grade Serous Ovarian Cancer
- Interventions
- First Posted Date
- 2024-05-01
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT06394804
- Locations
- πΊπΈ
Emory Winship Cancer Institute, Atlanta, Georgia, United States
πΊπΈMemorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
πΊπΈMemorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer
- Conditions
- Advanced Colorectal Cancer
- Interventions
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 33
- Registration Number
- NCT06369259
- Locations
- πΊπΈ
MD Anderson Cancer Center, Houston, Texas, United States
Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2025-01-30
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 33
- Registration Number
- NCT06194929
- Locations
- πΊπΈ
University of Iowa, Iowa City, Iowa, United States
πΊπΈHuntsman Cancer Institute, Salt Lake City, Utah, United States
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
- Conditions
- Low Grade Serous Ovarian Cancer
- Interventions
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Verastem, Inc.
- Target Recruit Count
- 270
- Registration Number
- NCT06072781
- Locations
- πΊπΈ
HonorHealth, Phoenix, Arizona, United States
πΊπΈUniversity of Arkansas, Little Rock, Arkansas, United States
πΊπΈUCLA Health, Los Angeles, California, United States
A Study of Avutometinib and Defactinib in People With Thyroid Cancer
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT06007924
- Locations
- πΊπΈ
Lehigh Valley Health Network (Data Collection Only), Allentown, Pennsylvania, United States
πΊπΈMemorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
πΊπΈMemorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma
- Conditions
- Recurrent GlioblastomaGlioblastoma
- Interventions
- First Posted Date
- 2023-04-04
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Emory University
- Target Recruit Count
- 12
- Registration Number
- NCT05798507
- Locations
- πΊπΈ
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer
- Conditions
- Mesonephric Gynecologic Cancer
- Interventions
- First Posted Date
- 2023-03-28
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT05787561
- Locations
- πΊπΈ
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
πΊπΈMemorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
πΊπΈMemorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.